Common variants in mismatch repair genes and risk of invasive ovarian cancer

被引:67
作者
Song, Honglin [1 ]
Ramus, Susan J.
Quaye, Lydia
DiCioccio, Richard A.
Tyrer, Jonathan
Lomas, Emma
Shadforth, Danielle
Hogdall, Estrid
Hogdall, Claus
McGuire, Valerie
Whittemore, Alice S.
Easton, Douglas F.
Ponder, Bruce A. J.
Kjaer, Susanne Kruger
Pharoah, Paul D. P.
Gayther, Simon A.
机构
[1] Univ Cambridge, Strangeways Res Lab, CR UK Dept Oncol, Cambridge CB2 1TN, England
[2] UCL, Dept Gynaecol Oncol, Translat Res Lab, London WC1E 6BT, England
[3] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA
[4] Danish Canc Soc, Dept Viruses Hormones & Canc, Inst Canc Epidemiol, Copenhagen, Denmark
[5] Univ Copenhagen, Rigshosp, Juliane Marie Ctr, Gynaecol Clin, Copenhagen, Denmark
[6] Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.1093/carcin/bgl089
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mismatch repair (MMR) is important for repairing of nucleotide mismatches during DNA replication. Germline mutations in MMR genes are associated with hereditary non-polyposis colorectal cancer (HNPCC). Ovarian cancer occurs as part of the HNPCC phenotype, and so common variants in MMR genes are candidates for ovarian cancer susceptibility. We performed a large multicentre case-control study to investigate associations of common variations in MMR genes and ovarian cancer using a single nucleotide polymorphism (SNP) tagging approach. A total of 2570 controls and 1531 cases from three separate studies were genotyped for 44 tagging SNPs (stSNP) in seven MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 and PMS2). Genotype frequencies were marginally different between cases and controls for PMS2 rs7797466 (P-2df = 0.046) with a 1.17-fold (95% CI 1.03-1.33) increase in risk for each 'a' allele carried (P-trend = 0.013). Haplotype analysis of PMS2 also showed significant differences in frequencies between cases and controls (P-7df = 0.005), with one haplotype accounting for most of the effect. There was also marginal evidence for a recessive protective effect with common homozygote as the baseline comparator for two SNPs-MSH6 rs3136245 (OR 0.67; 95% CI 0.46-0.98) and MSH3 rs6151662 (OR 0.28; 95% CI 0.08-0.91)-but the comparisons of genotype frequencies for these variants were not significant (P = 0.10 and 0.054). In conclusion, it is unlikely that common variants in MLH1, MLH3, PMS1, MSH2, MSH3 and MSH6 contribute significantly to ovarian cancer susceptibility. The observed association of PMS2 rs7797466 with ovarian cancer warrants confirmation in an independent study.
引用
收藏
页码:2235 / 2242
页数:8
相关论文
共 28 条
[1]   Microsatellite instability differences between familial and sporadic ovarian cancers [J].
Arzimanoglou, II ;
Lallas, T ;
Osborne, M ;
Barber, H ;
Gilbert, F .
CARCINOGENESIS, 1996, 17 (09) :1799-1804
[2]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[3]   Mammalian DNA mismatch repair [J].
Buermeyer, AB ;
Deschênes, SM ;
Baker, SM ;
Liskay, RM .
ANNUAL REVIEW OF GENETICS, 1999, 33 :533-564
[4]   Population stratification and spurious allelic association [J].
Cardon, LR ;
Palmer, LJ .
LANCET, 2003, 361 (9357) :598-604
[5]  
Chen Y, 2003, INT J ONCOL, V22, P1033
[6]   Mechanisms of human DNA repair: an update [J].
Christmann, M ;
Tomicic, MT ;
Roos, WP ;
Kaina, B .
TOXICOLOGY, 2003, 193 (1-2) :3-34
[7]   The contribution of DNA mismatch repair gene defects to the burden of gynecological cancer [J].
Drake, AC ;
Campbell, H ;
Porteous, MEM ;
Dunlop, MG .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (03) :262-277
[8]   Guidelines for association studies in human molecular genetics [J].
Freimer, NB ;
Sabatti, C .
HUMAN MOLECULAR GENETICS, 2005, 14 (17) :2481-2483
[9]   Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma [J].
Geisler, JP ;
Goodheart, MJ ;
Sood, AK ;
Holmes, RJ ;
Hatterman-Zogg, MA ;
Buller, RE .
CANCER, 2003, 98 (10) :2199-2206
[10]  
Gras E, 2001, CANCER-AM CANCER SOC, V92, P2829, DOI 10.1002/1097-0142(20011201)92:11<2829::AID-CNCR10094>3.0.CO